首页> 美国卫生研究院文献>BMC Systems Biology >Regulation of dual specificity phosphatases in breast cancer during initial treatment with Herceptin: a Boolean model analysis
【2h】

Regulation of dual specificity phosphatases in breast cancer during initial treatment with Herceptin: a Boolean model analysis

机译:赫赛汀初始治疗期间乳腺癌双特异性磷酸酶的调节:布尔模型分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background25% of breast cancer patients suffer from aggressive HER2-positive tumours that are characterised by overexpression of the HER2 protein or by its increased tyrosine kinase activity. Herceptin is a major drug used to treat HER2 positive breast cancer. Understanding the molecular events that occur when breast cancer cells are exposed to Herceptin is therefore of significant importance. Dual specificity phosphatases (DUSPs) are central regulators of cell signalling that function downstream of HER2, but their role in the cellular response to Herceptin is mostly unknown. This study aims to model the initial effects of Herceptin exposure on DUSPs in HER2-positive breast cancer cells using Boolean modelling.
机译:背景技术25%的乳腺癌患者患有侵袭性HER2阳性肿瘤,其特征是HER2蛋白过表达或酪氨酸激酶活性增强。赫赛汀是一种用于治疗HER2阳性乳腺癌的主要药物。因此,了解当乳腺癌细胞暴露于赫赛汀时发生的分子事件非常重要。双重特异性磷酸酶(DUSPs)是在HER2下游起作用的细胞信号传导的中央调节剂,但在细胞对赫赛汀的反应中的作用尚不清楚。这项研究旨在使用布尔模型来模拟赫赛汀暴露对HER2阳性乳腺癌细胞中DUSP的初始作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号